Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...

Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HONG KONG and SHANGHAI and ...

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

Investing.com -- HUTCHMED (NASDAQ:HCM) stock gained 1.9% in premarket trading Wednesday after the company announced that its Phase III trial of sovleplenib in patients with warm antibody autoimmune ...

Autoimmune hemolytic anemia (AIHA) is a rare but clinically significant disorder in which the immune system mistakenly produces autoantibodies against red blood cells, leading to accelerated ...

Medically reviewed by Jordana Haber Hazan, MD Hemolytic anemia occurs when red blood cells are destroyed faster than they can ...

Cold agglutinin disease is a condition that causes low red blood cell (RBC) counts. Symptoms can include fatigue, weakness, or shortness of breath. Cold agglutinin disease is a type of autoimmune ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune ...